Edition:
India

Biocartis Group Announces Positive Study Results On Idylla Msi And Ras Liquid Biopsy Tests


Friday, 19 Oct 2018 

Oct 19 (Reuters) - BIOCARTIS GROUP NV ::RESULTS OF STUDY SHOWED IDYLLA(TM) LIQUID BIOPSY CTRAS-BRAF TESTS CAN PREDICT TREATMENT OUTCOME IN PATIENTS WITH MCRC.SECOND STUDY REVEALED POSITIVE PERFORMANCE OF PROTOTYPE IDYLLA(TM) MSI TEST BASED ON CONCORDANCE COMPARED TO OTHER TESTING METHODS FREQUENTLY USED.CONCORDANCE OF 98.7% WAS ACHIEVED WITH PROMEGA MSI ANALYSIS SYSTEM AND A CONCORDANCE OF 97.6% WITH IMMUNOHISTOCHEMICAL (IHC) ANALYSIS.SECOND STUDY DEMONSTRATES ROBUSTNESS OF IDYLLA(TM) MSI ASSAY, WHICH PROVIDES INFORMATION ON MSI STATUS OF TUMOR IN RAPID AND EASY WAY.THE STUDIES ON IDYLLA(TM) MSI AND RAS LIQUID BIOPSY TESTS TO BE PRESENTED AT ESMO CONGRESS. 

Company Quote

6.08
 --
18 Nov 2019